Medicus Pharma Ltd.
$0.34
▲
6.43%
2026-04-21 08:05:01
medicuspharma.com
NCM: MDCX
Explore Medicus Pharma Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.54 M
Current Price
$0.34
52W High / Low
$8.94 / $0.29
Stock P/E
—
Book Value
$-0
Dividend Yield
—
ROCE
-27863.04%
ROE
-29.81%
Face Value
—
EPS
$-2.74
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
16
Beta
-0.04
Debt / Equity
14,679.33
Current Ratio
0.99
Quick Ratio
1
Forward P/E
-1.02
Price / Sales
—
Enterprise Value
$13.17 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$10.53
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Organon & Co. | $9.26 | 12.89 | $2.41 B | 0.86% | 11.7% | 30.56% | $13.24 / $5.69 | $2.89 |
| 2. | AbbVie Inc. | NOT FOUND | 86.59 | $360.82 B | 3.4% | 22.16% | 62.25% | $244.81 / $168.54 | $-1.85 |
| 3. | Amgen Inc. | $346.69 | 24.37 | $187.08 B | 2.84% | 13.95% | 1.06% | $391.29 / $261.43 | $16.07 |
| 4. | Nasus Pharma Ltd. | $2.86 | — | $19.29 M | — | -172.62% | 2637.84% | $9.99 / $1.98 | $0.31 |
| 5. | Eli Lilly and Company | $921 | 40.12 | $868.52 B | 0.75% | 38.44% | 1.01% | $1,133.95 / $623.78 | $29.66 |
| 6. | Pfizer Inc. | $26.9 | 19.83 | $152.79 B | 6.25% | 10.17% | 8.89% | $28.75 / $21.87 | $15.21 |
| 7. | Novartis AG | $147.76 | 20.66 | $301.93 B | 3.13% | 21.09% | 30.81% | $131 / $87.89 | $24.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -7.79 M | -15.43 M | -6.02 M | -5.13 M | -2.35 M | — |
| Net Profit | -8.18 M | -15.98 M | -6.18 M | -5.1 M | -2.27 M | — |
| EPS in Rs | -0.21 | -0.41 | -0.16 | -0.13 | -0.06 | -0.24 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -34.36 M | -11.18 M | -2.66 M | -0.98 M |
| Net Profit | -35.44 M | -11.16 M | -5.31 M | -1.69 M |
| EPS in Rs | -0.9 | -0.28 | -0.14 | -0.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 10.06 M | 5.65 M | 1.89 M | 0.28 M |
| Total Liabilities | 10.02 M | 2.51 M | 0.78 M | 12.48 M |
| Equity | -0.07 M | 3.13 M | 1.11 M | -12.2 M |
| Current Assets | 9.89 M | 5.38 M | 1.89 M | 0.28 M |
| Current Liabilities | 9.94 M | 2.31 M | 0.78 M | 12.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -22.78 M | -10.25 M | -4.16 M | -1.06 M |
| Investing CF | -4.62 M | 0 M | — | — |
| Financing CF | 31.94 M | 12.69 M | 5.61 M | 1.25 M |
| Free CF | -22.78 M | -10.25 M | -4.16 M | -1.06 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -109.9% | -214.04% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.